Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2005
10/06/2005WO2005092323A1 PARTIAL AGONIST SPECIFIC TO LXRα RECEPTOR
10/06/2005WO2005092322A1 Natural compound causing rar activation
10/06/2005WO2005092321A1 Pharmaceutical composition for prevention or treatment of increased urinary frequency or involuntary urination
10/06/2005WO2005092320A1 Cytoprotective composition
10/06/2005WO2005092319A1 Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant
10/06/2005WO2005092318A1 Combinations comprising alpha-2-delta ligands
10/06/2005WO2005092316A1 Novel pharmaceutical compositions comprising agonists of the thyroid receptor
10/06/2005WO2005092315A1 Use of n-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
10/06/2005WO2005092314A1 4-oxo-fenretinide, administered alone and in combination with fenretinide, as preventive and therapeutic agent for cancer
10/06/2005WO2005092313A1 Novel use of peptide compounds for treating pain in painful diabetic neuropathy
10/06/2005WO2005092312A1 A radiosensitizer comprising oleamide
10/06/2005WO2005092311A1 Use of metformin and orlistat for the treatment or prevention of obesity
10/06/2005WO2005092310A2 Chemically stable compositions of 4-hydroxy tamoxifen
10/06/2005WO2005092309A1 Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
10/06/2005WO2005092308A2 Neural tourniquet
10/06/2005WO2005092307A2 Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists
10/06/2005WO2005092306A1 Methods and compositions for modulating opioid tolerance and chronic pain
10/06/2005WO2005092305A2 Compounds for treating aids and other diseases
10/06/2005WO2005092304A2 Antifungal agents
10/06/2005WO2005092303A2 Combination therapy with azd2171 and 5-fu and/or cpt-11
10/06/2005WO2005092302A2 Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen
10/06/2005WO2005092300A1 Method of making silicone pressure sensitive adhesives for delivering hydrophilic drugs using a silicone polyether
10/06/2005WO2005092297A2 A stable pharmaceutical composition comprising an acid labile drug
10/06/2005WO2005092296A1 Edible microcrystalline cellulose and carrageenan coating composition
10/06/2005WO2005092295A1 Gastroresistant pharmaceutical dosage form comprising n-(2-(2-phthalimidoethoxy)-acetyl)-l-alanyl-d-glutamic acid (lk-423)
10/06/2005WO2005092294A1 Oral matrix formulations comprising licarbazepine
10/06/2005WO2005092293A1 Formulations of metformin
10/06/2005WO2005092291A1 Prolonged-release compositions comprising torasemide and a matrix-forming polymer
10/06/2005WO2005092290A1 Disintegrating tablets comprising licarbazepine
10/06/2005WO2005092287A1 Bioavailable nutritional supplement and method of treatment of malabsorption
10/06/2005WO2005092264A1 Drug-enhanced adhesion prevention
10/06/2005WO2005092123A1 Solubilized coq-10 and carnitine
10/06/2005WO2005092099A1 Hiv integrase inhibitors
10/06/2005WO2005092097A1 Compositions and methods for targeting metastatic tumors using multivalent ligand-linked carbohydrate polymers
10/06/2005WO2005092096A1 Single tank process for preparing tannate liquid and semi-solid dosage forms
10/06/2005WO2005092066A2 Imidazole compounds
10/06/2005WO2005092058A2 Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses
10/06/2005WO2005092040A2 A formulation for increasing endogenous adiponectin and leptin production
10/06/2005WO2005092039A2 Crosslinked amine polymers
10/06/2005WO2005091991A2 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
10/06/2005WO2005091967A2 Methods and compositions for ophthalmic treatment of fungal and bacterial infections
10/06/2005WO2005091909A2 Methods to increase reverse cholesterol transport in the retinal pigment epithelium (rpe) and bruch’s membrane (bm)
10/06/2005WO2005091872A2 Pharmaceutical composition and method for the transdermal delivery of magnesium
10/06/2005WO2005091754A2 Novel cyclopentenedione antifungal compounds and methods for their use
10/06/2005WO2005091752A2 Acrylonitrile derivatives for inflammation and immune-related uses
10/06/2005WO2005091716A2 Annexin ii and uses thereof
10/06/2005WO2005077126A9 Use of ppargamma specific inhibitors as anti-cancer therapeutics
10/06/2005WO2005076731A3 High salt compositions, methods of producing same and methods of use thereof
10/06/2005WO2005075471A3 Thiazol-compounds as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
10/06/2005WO2005075427A3 Montelukast sodium polymorphs
10/06/2005WO2005075420A3 Pyrrolidine derivatives acting as ccr3-receptor antagonists
10/06/2005WO2005074929A3 Calcium, potassium, zinc, lithium and aluminium salts of pantoprazole and (s)-pantoprazole
10/06/2005WO2005074897A3 Formulation auxiliary agents (aminopropanoic acid derivative) in cosmetic or dermatological preparations
10/06/2005WO2005073234A3 Imidazo[1,2-c]pyrimidinylacetic acid derivatives
10/06/2005WO2005072893A8 Functionalized colloidal metal compositions and methods
10/06/2005WO2005072066A3 Preventive or therapeutic agent for diabetic maculopathy
10/06/2005WO2005069894A3 Conformationally constrained smac mimetics and the uses thereof
10/06/2005WO2005066135A3 Pyrrole and pyrazole daao inhibitors
10/06/2005WO2005065661A3 Immediate, controlled and sustained release formulations of galanthamine
10/06/2005WO2005063294A8 Inhibitor for the formation of ϝ-secretase complex
10/06/2005WO2005062851A3 Indole-3-propionamide and derivatives thereof
10/06/2005WO2005058934A3 Glycosylated steroid derivatives with anti-migratory activity
10/06/2005WO2005055928A3 Zn2+ -chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
10/06/2005WO2005055923A3 Method for treating athlete´s foot
10/06/2005WO2005048955A3 Preloading with macular pigment to improve photodynamic treament of retinal vascular disorders
10/06/2005WO2005046720A3 Diagnosis, prognosis and treatment of pulmonary diseases using foxa2
10/06/2005WO2005046599A3 Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
10/06/2005WO2005044180A3 Methods of reducing risk of infection from pathogens
10/06/2005WO2005041951A3 Rhodanine derivatives for use as antiviral agents
10/06/2005WO2005041879A3 COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA
10/06/2005WO2005039588A3 Methods for determining the risk of developing liver and lung toxicity
10/06/2005WO2005039499A3 Rapidly disintegrating film
10/06/2005WO2005039485B1 Gsk-3 inhibitors and uses thereof
10/06/2005WO2005037200B1 Composition comprising xanthoceras sorbifolia extracts, compounds isolated from same, methods for preparing same and uses thereof
10/06/2005WO2005032477A3 Gamma-tocopherol treatment for cystic fibrosis
10/06/2005WO2005023240A3 Pharmaceutical combination preparation containing glycyrrhizine, zinc, and a compound comprising a thiol group or a group that is metabolized thereto
10/06/2005WO2005020921A3 C-kit modulators and methods of use
10/06/2005WO2005019434A3 Serine protease inhibitors for treatment of bacterial infections
10/06/2005WO2005018641A3 Novel use of quinolone antibiotics
10/06/2005WO2005018550A3 Enhancement of magnesium uptake in mammals
10/06/2005WO2005016254A3 Methods and reagents for treating inflammation and fibrosis
10/06/2005WO2005016080A3 Folding table and bench system
10/06/2005WO2005009344A3 Acylated amino acid amidyl pyrazoles and related compounds
10/06/2005WO2005007110A3 Compositions and methods for hydrophobic drug delivery
10/06/2005WO2005002551A3 Vanilloid receptor (vr) 1 inhibitors for treatment of human immunodeficiency virus (hiv)-mediated pain states
10/06/2005WO2005000850B1 Novel crystalline forms of valacyclovir hydrochloride
10/06/2005WO2004108114A3 Anti-fungal composition and a process for its manufacture
10/06/2005WO2004091527B1 Delivery systems of homogeneous thermoreversible low viscosity polymannan gum films
10/06/2005WO2004041193A3 HUMAN TYPE II DIABETES GENE-Kv CHANNEL-INTERACTING PROTEIN (KChIP1) LOCATED ON CHROMOSOME 5
10/06/2005WO2004032877A3 Compositions, organisms and methodologies employing a novel human kinase
10/06/2005US20050223369 Method and system for programming a reconfigurable processing element
10/06/2005US20050222959 Method for marketing rights to intellectual assets
10/06/2005US20050222615 Hemostasis pad and method
10/06/2005US20050222424 Phenyloxyalkanonic acid derivatives as hppar activators
10/06/2005US20050222423 Carboxylic acid derivative
10/06/2005US20050222420 Chain oligolactic acid thioester
10/06/2005US20050222419 Process for preparing pesticidal intermediates
10/06/2005US20050222418 Novel tyloindicines and related processes, pharmaceutical compositions and methods
10/06/2005US20050222414 N-(4-methylphenyl)-4-[4-[[(phenylmethoxy)amino]carbonyl]phenyl]-1-piperazinecarboxamide; anticarcinogenic, antiproliferative agent; ovarian carcinoma, psoriasis; gene transcription control
10/06/2005US20050222413 (Famciclovir); reacting the thallium salt of 2-aminopurine and 2-acetoxymethyl-4-bromobut-1-yl-acetate in a polar organic solvent under mild reaction conditions; selective coupling at the 9-position; by-product inhibition; antiviral drug
1 ... 4513 4514 4515 4516 4517 4518 4519 4520 4521 4522 4523 4524 4525 4526 4527 4528 4529 4530 4531 4532 4533 ... 7860